European Union - English - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - hiv infections - antivirals for systemic use - agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (pi) experienced hiv-1 infected adults and children above the age of 4 years. agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). the choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).the benefit of agenerase boosted with ritonavir has not been demonstrated in pi nave patients (see section 5.1)

Canada - English - Health Canada

glaxosmithkline inc - amprenavir - capsule - 50mg - amprenavir 50mg - hiv protease inhibitors

Canada - English - Health Canada

glaxosmithkline inc - amprenavir - capsule - 150mg - amprenavir 150mg - hiv protease inhibitors

Canada - English - Health Canada

glaxosmithkline inc - amprenavir - liquid - 15mg - amprenavir 15mg - hiv protease inhibitors

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amprenavir - capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amprenavir - oral solution - 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amprenavir - oral solution - 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amprenavir - oral solution - 15mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - amprenavir - capsule - 50mg